We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

70 hedge funds and large institutions have $610M invested in Blueprint Medicines in 2015 Q2 according to their latest regulatory filings, with 70 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
70
Holders Change
+70
Holders Change %
–
% of All Funds
1.89%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
70
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRV
Third Rock Ventures
Massachusetts
+$211M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$116M
3
BI
BVF Inc
California
+$45.2M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$32.6M
5
VAM
Visium Asset Management
New York
+$27M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
TRV
1
Third Rock Ventures
Massachusetts
$196M +$211M +7,393,059 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$108M +$116M +4,066,710 New
BI
3
BVF Inc
California
$41.9M +$45.2M +1,582,408 New
Wellington Management Group
4
Wellington Management Group
Massachusetts
$30M +$32.6M +1,140,878 New
VAM
5
Visium Asset Management
New York
$25M +$27M +945,000 New
RCM
6
RA Capital Management
Massachusetts
$23.3M +$25.1M +878,348 New
PHS
7
PFM Health Sciences
California
$20.9M +$24.6M +862,165 New
Lord, Abbett & Co
8
Lord, Abbett & Co
New Jersey
$19.5M +$21M +735,419 New
Citadel Advisors
9
Citadel Advisors
Florida
$18.1M +$19.5M +683,584 New
DCM
10
Driehaus Capital Management
Illinois
$13.5M +$14.5M +507,827 New
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$13.3M +$14.4M +503,550 New
RIM
12
RS Investment Management
California
$13M +$14.1M +492,510 New
PA
13
Perceptive Advisors
New York
$10.7M +$11.5M +404,404 New
RG
14
Redmile Group
California
$9.67M +$10.8M +378,235 New
SM
15
Sabby Management
Florida
$8M +$8.62M +301,804 New
JP Morgan Chase
16
JP Morgan Chase
New York
$6.94M +$7.48M +261,850 New
BFA
17
BlackRock Fund Advisors
California
$6.5M +$7M +245,255 New
Ameriprise
18
Ameriprise
Minnesota
$5.19M +$5.6M +196,096 New
Vanguard Group
19
Vanguard Group
Pennsylvania
$4.9M +$5.28M +184,871 New
BIT
20
BlackRock Institutional Trust
California
$3.24M +$3.49M +122,260 New
UBS AM
21
UBS AM
Illinois
$3.16M +$3.41M +119,279 New
CAM
22
Cormorant Asset Management
Massachusetts
$2.65M +$2.86M +100,000 New
PI
23
Putnam Investments
Massachusetts
$2.63M +$2.84M +99,300 New
Millennium Management
24
Millennium Management
New York
$2.12M +$2.29M +80,200 New
ACH
25
ArrowMark Colorado Holdings
Colorado
$2.08M +$2.25M +78,612 New
1
2 3

BPMC Hedge Fund Activity: Q2 2015 in Review

70 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q2 2015, worth a combined $610M.

Buyers outnumbered sellers: 70 funds opened new BPMC positions and 0 closed out — a net gain of 70 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Third Rock Ventures, opening a new position worth an estimated $211M.

  • 70 institutional investors held Blueprint Medicines (BPMC) as of Q2 2015, up from 0 in Q1 2015.
  • Funds reported $610M of Blueprint Medicines stock for Q2 2015.
  • 70 funds opened new Blueprint Medicines positions in Q2 2015 and 0 closed out, a net change of +70 holders.
  • The largest Blueprint Medicines buyer in Q2 2015 was Third Rock Ventures, an estimated $211M added.

Based on aggregated 13F filings for Q2 2015.